Kala Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	0	3.89	11.24	6.36	6.07	0	0	0	0.05
Revenue Growth (YoY)	-	-65.37%	76.67%	4.74%	-	-	-	-	-
Cost of Revenue	0	2.56	4.1	3.17	2.01	0	0	0	0
Gross Profit	0	1.33	7.14	3.19	4.07	0	0	0	0.05
Selling, General & Admin	20.57	65.04	105.06	81.07	65.02	35.43	10.87	7.64	4.61
Research & Development	18.59	17.65	11.52	18.35	27.28	29.29	29.01	25.03	11.38
Other Operating Expenses	-0.23	0.64	20.81	0	0	0	0	0	0
Operating Expenses	38.92	83.33	137.39	99.42	92.29	64.72	39.88	32.67	15.99
Operating Income	-38.92	-81.99	-130.25	-96.23	-88.22	-64.72	-39.88	-32.67	-15.95
Interest Expense / Income	5.81	7.27	8.38	8.59	8.48	3.31	1.02	0.77	0.6
Other Expense / Income	-2.54	-44.44	3.98	-0.49	-2.36	-1.3	1.32	-0.27	0.13
Pretax Income	-42.2	-44.82	-142.61	-104.33	-94.35	-66.74	-42.21	-33.17	-16.68
Net Income	-42.2	-44.82	-142.61	-104.33	-94.35	-66.74	-42.21	-33.17	-16.68
Shares Outstanding (Basic)	2	2	1	1	1	1	0	0	0
Shares Outstanding (Diluted)	2	2	1	1	1	1	0	0	0
Shares Change	59.94%	15.50%	25.67%	53.11%	27.87%	135.20%	862.80%	5.46%	-
EPS (Basic)	-17.35	-29.48	-108.32	-99.50	-138.00	-124.50	-185.50	-1403.50	-744.50
EPS (Diluted)	-17.35	-29.48	-108.32	-99.50	-138.00	-124.50	-185.50	-1403.50	-744.50
Free Cash Flow	-28.49	-79.11	-109.03	-92.64	-94.06	-55.7	-34.58	-27.5	-15.34
Free Cash Flow Per Share	-11.71	-52.02	-82.82	-88.43	-137.47	-104.09	-151.99	-1163.89	-684.70
Gross Margin	-	34.22%	63.55%	50.13%	66.94%	-	-	-	100.00%
Operating Margin	-	-2106.73%	-1158.76%	-1512.59%	-1452.49%	-	-	-	-35435.56%
Profit Margin	-	-1151.64%	-1268.73%	-1639.85%	-1553.29%	-	-	-	-37071.11%
Free Cash Flow Margin	-	-2032.55%	-970.01%	-1456.08%	-1548.49%	-	-	-	-34091.11%
EBITDA	-35.91	-36.58	-131.92	-92.9	-83.25	-62.47	-40.55	-32.1	-15.75
EBITDA Margin	-	-939.88%	-1173.62%	-1460.20%	-1370.61%	-	-	-	-34995.56%
Depreciation & Amortization	0.47	0.98	2.31	2.84	2.62	0.96	0.64	0.3	0.33
EBIT	-36.39	-37.56	-134.23	-95.74	-85.87	-63.42	-41.19	-32.4	-16.08
EBIT Margin	-	-964.95%	-1194.17%	-1504.84%	-1413.68%	-	-	-	-35728.89%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).